Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs International Business Machines Corp (IBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs International Business Machines Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while International Business Machines Corp trades at $235.5 (market cap $224.62B). The key difference: International Business Machines Corp is far larger — about 7.6× Alnylam Pharmaceuticals, Inc.'s market cap, and International Business Machines Corp pays a 2.84% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | IBM | |
|---|---|---|
Market Cap | $29.60B | $224.62B |
Sector | Health | Technology |
52-Week High | $491.22 | $329.23 |
52-Week Low | $205.48 | $205.77 |
Enterprise Value | $27.56B | $281.76B |
Volume | — | 4,481,527 |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
IBM trades at $234.91, down 0.59% today, with a mixed technical outlook showing bearish moving averages but bullish overall signals. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results pending. The company secured a $240 million AI deal with Together AI, boosting sentiment, but faces a securities fraud investigation following a 25% stock drop. Fundamentals are solid with revenue growth to $67.54 billion in 2025 and a net income margin of 15.52%, though cash flow turned negative.
Outlook is cautiously optimistic with a consensus price target of $257.38, implying 9.6% upside, supported by AI and cloud growth. Risks include the ongoing fraud probe, competitive pressures, and high debt levels. Investors should weigh strong profitability against legal and execution uncertainties in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →
